PF 4287881

Drug Profile

PF 4287881

Alternative Names: PF-04287881; PF-4287881

Latest Information Update: 18 May 2010

Price : $50

At a glance

  • Originator Pfizer
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Respiratory tract infections

Most Recent Events

  • 15 Sep 2009 Pharmacodynamics data from a preclinical study in Bacterial infections presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009) ,
  • 31 Dec 2008 Phase-I clinical trials in Bacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top